Dynavax Technologies Corporation (NASDAQ:DVAX) issued a press release announcing its financial results for the first quarter ended March 31, 2014. Dynavax Technologies Corporation (NASDAQ:DVAX) shares after opening at $1.52 moved to $1.59 on last trade day and at the end of the day closed at $1.57. Company price to sales ratio in past twelve months was calculated as 36.52 and price to cash ratio as 2.18. Dynavax Technologies Corporation (NASDAQ:DVAX) showed a positive weekly performance of 3.97%.
Alere Inc. (NYSE:ALR), a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, announces that it has separated the roles of Chairman of the Board and Chief Executive Officer. The Board of Directors unanimously elected Gregg J. Powers as Chairman of the Board of Alere, while Ron Zwanziger will continue as President, Chief Executive Officer and a member of the Board of Directors. Alere Inc (NYSE:ALR) shares advanced 4.87% in last trading session and ended the day on $35.50. ALR return on equity ratio is recorded as -6.90% and its return on assets is -1.60%. Alere Inc (NYSE:ALR) yearly performance is 30.95%.
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) announced that it will report its first quarter 2014 financial results on Thursday, May 8, 2014 at approximately 8:00 a.m. ET. The press release will be followed by a conference call and webcast at 8:30 a.m. ET. NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) shares moved up 3.96% in last trading session and was closed at $28.64 while trading in range of $26.37 – $29.01 – NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) year to date (YTD) performance is -5.67%.
Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) a fully integrated specialty biopharmaceutical company, announced financial results for the first quarter ending March 31, 2014. The Company highlighted important commercial, regulatory and clinical development updates from the quarter and, as previously announced, revised its 2014 financial guidance, principally related to lower expectations for Testim® revenues for the year. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) weekly performance is -19.35%. On last trading day company shares ended up $21.50. Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL) distance from 50-day simple moving average (SMA50) is -23.17%. Analysts mean target price for the company is $29.29.